We are live on
!
Find out more
Kiniksa Pharmaceuticals
KNSA
KNSA
92 hedge funds and large institutions have $290M invested in Kiniksa Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 37 increasing their positions, 26 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
114% more call options, than puts
Call options by funds: $3.32M | Put options by funds: $1.55M
42% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 26
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.96% less ownership
Funds ownership: 90.27% → 87.3% (-3%)
4% less funds holding
Funds holding: 96 → 92 (-4)
5% less capital invested
Capital invested by funds: $306M → $290M (-$15.5M)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Holders
92
Holders Change
-4
Holders Change %
-4.17%
% of All Funds
1.55%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
37
Reduced
26
Closed
9
Calls
$3.32M
Puts
$1.55M
Net Calls
+$1.77M
Net Calls Change
+$1.1M
Top Buyers
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$4.88M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$3.11M |
| 3 |
Walleye Capital
New York
|
+$1.81M |
| 4 |
Morgan Stanley
New York
|
+$1.75M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.09M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$6.78M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.28M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$3.01M |
| 4 |
Goldman Sachs
New York
|
-$2.82M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.78M |
